This highlights the potential of targeted therapy in rare brain tumors, warranting further prospective randomized clinical trials such as an ongoing targeted therapy approach of Dabrafenib and Trametinib in pediatric patients with BRAF-mutated high-grade and low-grade gliomas, currently under phase II. The gene discussed is BRAF; the disease is glioma.